Efficacy and safety of selective arginine vasopressin V2 receptor antagonist for the syndrome of inappropriate antidiuretic hormone secretion

Objective To observe the efficacy and safety of tolvaptan,a selective arginine vasopressin(AVP)V2receptor antagonist,on the syndrome of inappropriate antidiuretic hormone secretion(SIADH). Methods Three SIADH patients treated by tolvaptan in 2 clinical centers between December 2012 and Steptember 2013were analyzed retrospectively.The clinical and laboratory features before and after therapy were compared.Results All the 3patients recruited by the criteria of SIADH achieved normonatremic level by 3.75mg/d to 22.5mg/d tolvaptan therapy.No severe adverse reaction occurred.Conclusion SIADH can be improved effectively by selective vasopressin V2receptor antagonist.However,there is great individual difference in curative dose.